A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder

Sharon B. Wigal; James J. McGough; James T. McCracken; Joseph Biederman; Thomas J. Spencer; Kelly L. Posner; Tim L. Wigal; Scott H. Kollins; Tanya M. Clark; David A. Mays; Yuxin Zhang; Simon J. Tulloch

doi:10.1177/1087054705281121

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder

Sharon B. Wigal
, James J. McGough
, James T. McCracken
, Joseph Biederman
, Thomas J. Spencer
, Kelly L. Posner
, Tim L. Wigal
, Scott H. Kollins
, Tanya M. Clark
, David A. Mays
, Yuxin Zhang
, Simon J. Tulloch

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

Mixed amphetamine salts extended release (MAS XR; Adderall XR®) and atomoxetine (Strattera®) were compared in children 6 to 12 years old with attention deficit/hyperactivity disorder (ADHD) combined or hyperactive/ impulsive type in a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study. Primary efficacy measure was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) behavioral rating scale. Changes in mean SKAMP deportment scores from baseline were significantly greater for MAS XR (n = 102) than for atomoxetine (n = 101) overall (-0.56 and -0.13, respectively; p < .0001) and at each week (p < .001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of MAS XR suggests that it is more effective than atomoxetine in children with ADHD.

Original language	English
Pages (from-to)	275-289
Number of pages	15
Journal	Journal of Attention Disorders
Volume	9
Issue number	1
DOIs	https://doi.org/10.1177/1087054705281121
State	Published - Aug 2005
Externally published	Yes

Keywords

ADHD
Adderall
Atomoxetine
Attention deficit/hyperactivity disorder
Mixed amphetamine salts
Strattera

Access to Document

10.1177/1087054705281121

Cite this

Wigal, S. B., McGough, J. J., McCracken, J. T., Biederman, J., Spencer, T. J., Posner, K. L., Wigal, T. L., Kollins, S. H., Clark, T. M., Mays, D. A., Zhang, Y., & Tulloch, S. J. (2005). A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder. Journal of Attention Disorders, 9(1), 275-289. https://doi.org/10.1177/1087054705281121

@article{083bf61211b44c3bbba36d52ff210ee4,

title = "A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR{\textregistered}) and atomoxetine (Strattera{\textregistered}) in school-aged children with attention deficit/hyperactivity disorder",

abstract = "Mixed amphetamine salts extended release (MAS XR; Adderall XR{\textregistered}) and atomoxetine (Strattera{\textregistered}) were compared in children 6 to 12 years old with attention deficit/hyperactivity disorder (ADHD) combined or hyperactive/ impulsive type in a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study. Primary efficacy measure was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) behavioral rating scale. Changes in mean SKAMP deportment scores from baseline were significantly greater for MAS XR (n = 102) than for atomoxetine (n = 101) overall (-0.56 and -0.13, respectively; p < .0001) and at each week (p < .001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of MAS XR suggests that it is more effective than atomoxetine in children with ADHD.",

keywords = "ADHD, Adderall, Atomoxetine, Attention deficit/hyperactivity disorder, Mixed amphetamine salts, Strattera",

author = "Wigal, \{Sharon B.\} and McGough, \{James J.\} and McCracken, \{James T.\} and Joseph Biederman and Spencer, \{Thomas J.\} and Posner, \{Kelly L.\} and Wigal, \{Tim L.\} and Kollins, \{Scott H.\} and Clark, \{Tanya M.\} and Mays, \{David A.\} and Yuxin Zhang and Tulloch, \{Simon J.\}",

year = "2005",

month = aug,

doi = "10.1177/1087054705281121",

language = "English",

volume = "9",

pages = "275--289",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications Inc.",

number = "1",

}

Wigal, SB, McGough, JJ, McCracken, JT, Biederman, J, Spencer, TJ, Posner, KL, Wigal, TL, Kollins, SH, Clark, TM, Mays, DA, Zhang, Y & Tulloch, SJ 2005, 'A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder', Journal of Attention Disorders, vol. 9, no. 1, pp. 275-289. https://doi.org/10.1177/1087054705281121

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder. / Wigal, Sharon B.; McGough, James J.; McCracken, James T. et al.
In: Journal of Attention Disorders, Vol. 9, No. 1, 08.2005, p. 275-289.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder

AU - Wigal, Sharon B.

AU - McGough, James J.

AU - McCracken, James T.

AU - Biederman, Joseph

AU - Spencer, Thomas J.

AU - Posner, Kelly L.

AU - Wigal, Tim L.

AU - Kollins, Scott H.

AU - Clark, Tanya M.

AU - Mays, David A.

AU - Zhang, Yuxin

AU - Tulloch, Simon J.

PY - 2005/8

Y1 - 2005/8

N2 - Mixed amphetamine salts extended release (MAS XR; Adderall XR®) and atomoxetine (Strattera®) were compared in children 6 to 12 years old with attention deficit/hyperactivity disorder (ADHD) combined or hyperactive/ impulsive type in a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study. Primary efficacy measure was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) behavioral rating scale. Changes in mean SKAMP deportment scores from baseline were significantly greater for MAS XR (n = 102) than for atomoxetine (n = 101) overall (-0.56 and -0.13, respectively; p < .0001) and at each week (p < .001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of MAS XR suggests that it is more effective than atomoxetine in children with ADHD.

AB - Mixed amphetamine salts extended release (MAS XR; Adderall XR®) and atomoxetine (Strattera®) were compared in children 6 to 12 years old with attention deficit/hyperactivity disorder (ADHD) combined or hyperactive/ impulsive type in a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study. Primary efficacy measure was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) behavioral rating scale. Changes in mean SKAMP deportment scores from baseline were significantly greater for MAS XR (n = 102) than for atomoxetine (n = 101) overall (-0.56 and -0.13, respectively; p < .0001) and at each week (p < .001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of MAS XR suggests that it is more effective than atomoxetine in children with ADHD.

KW - ADHD

KW - Adderall

KW - Atomoxetine

KW - Attention deficit/hyperactivity disorder

KW - Mixed amphetamine salts

KW - Strattera

UR - https://www.scopus.com/pages/publications/27644534213

U2 - 10.1177/1087054705281121

DO - 10.1177/1087054705281121

M3 - Article

C2 - 16371674

AN - SCOPUS:27644534213

SN - 1087-0547

VL - 9

SP - 275

EP - 289

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 1

ER -

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder

Abstract

Keywords

Access to Document

Fingerprint

Cite this